Current diagnostic methods for lower respiratory specimens typically take one to two days to identify most bacterial pathogens. During that time, clinicians must rely on guideline recommendations and clinical diagnosis to guide empiric therapy, which is not optimized based on the patient’s individual pathogen. The BioFire Pneumonia Panel will provide pathogen identification in a much shorter timeframe and may allow clinicians to optimize targeted pathogen-specific therapy sooner.
The BioFire Pneumonia Panel is a rapid multiplex-PCR test that identifies 33 targets, including 18 bacteria, 8 viruses and 7 antimicrobial resistance genes from lower respiratory tract specimens in about an hour. It provides semi-quantitative results (in copies/ml) for 15 of the bacterial targets. This new feature provided by multiplex-PCR testing may help clinicians and laboratorians separate colonizing from pathogenic levels of bacteria.
This webinar will discuss the current role of diagnostic testing for the diagnosis of pneumonia and how the BioFire Pneumonia Panel will fit into this landscape. Dr. Amanda Harrington, Director, Clinical Microbiology Laboratory, Loyola University Medical Center was a principal investigator on the BioFire Pneumonia Panel clinical evaluation. She will discuss the clinical performance of the BioFire Pneumonia Panel as well as share data from an evaluation of the testing performed in the clinical laboratory at Loyola University Medical Center.
Amanda T. Harrington, PhD, D(ABMM), Director, Clinical Microbiology Laboratory, Loyola University Medical Center
Amanda Harrington is an Associate Professor in the Department of Pathology and Laboratory Medicine at Loyola University Chicago and Director of the Clinical Microbiology Laboratory at Loyola University Medical Center in Maywood, IL. She earned her doctoral degree in microbiology from the University of Kansas, did her post-doctoral fellowship training in clinical microbiology at the University of Washington in Seattle, WA, and she is a diplomate of the American Board of Medical Microbiology. She is a member of the Association for Molecular Pathology as well as the South Central Association for Clinical Microbiology. She is currently serving as the President-Elect for the Illinois Society for Microbiology and is an active member of the American Society for Microbiology. Her research interests include rapid diagnostic and molecular-based testing and metrics based assessment of quality in clinical microbiology and infectious diseases.
Who Should Attend?
- Clinical Laboratory Professionals
- Infectious Disease Pharmacists
- Infectious Disease Physicians
- Pulmonary/Critical Care Physicians
What You Will Learn
- Hear from Dr. Amanda Harrington, Director, Clinical Microbiology Laboratory, Loyola University Medical Center and principal investigator on the BioFire Pneumonia Panel clinical evaluation
- Better understand the changes the BioFire Pneumonia Panel brings to the current state of diagnostic testing for pneumonia
- Review data from a clinical microbiology laboratory’s experience with the BioFire Pneumonia Panel
With more than 25 years of molecular experience, BioFire Diagnostics, LLC sets the standard for molecular diagnostics through its pioneering advances in syndromic infectious disease testing. The syndromic approach is a symptom-driven diagnostic method that combines a broad grouping of probable pathogenic causes into a single, rapid test. This allows physicians to easily choose the right test, the first time. Our innovative team leads the industry in infectious disease diagnostics and provides molecular solutions that lessen the time to medical results, empower healthcare professionals to make better diagnostic decisions and lower healthcare costs. We are committed to improving the quality of life for everyone, everywhere, every day.